American Journal of Clinical Dermatology

, Volume 14, Issue 3, pp 195–213 | Cite as

Diagnosis and Treatment of Pediatric Psoriasis: Current and Future

  • Kara N. ShahEmail author
Review Article


Psoriasis is a common yet complex inflammatory dermatosis that may be seen in infants, children, and adolescents. The clinical presentation and course may be quite variable, and while patients with mild disease are often easily managed, those with recalcitrant or more severe disease often present a therapeutic dilemma given the number of therapies available and the relative lack of data on the efficacy and safety of use of these therapies in children. This review presents the reader with an overview of the current understanding of the pathophysiology, diagnosis, and treatment of pediatric psoriasis, with an emphasis on the available data in the literature that pertains to the use in children of currently available topical and systemic therapies, including topical corticosteroids, vitamin D analogs, phototherapy, systemic immunosuppressive medications, and biologic agents.


Psoriasis Juvenile Idiopathic Arthritis Plaque Psoriasis Acitretin Tazarotene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were received to prepare this article. The author has no conflicts of interest that are directly relevant to the content of this article. The author would like to thank Dr. Kelly Cordoro for her critical review of therapeutic recommendations.


  1. 1.
    Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermtol. 1985;13(3):450–6.CrossRefGoogle Scholar
  2. 2.
    Fan X, Xiao FL, Yang S, et al. Childhood psoriasis: a study of 277 patients from China. JEADV. 2007;21(6):762–5.PubMedGoogle Scholar
  3. 3.
    Henseler T. The genetics of psoriasis. J Am Acad Dermatol. 1997;37(2 Pt 3):S1–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Farber EM, Nall ML. Epidemiology: natural history and genetics. In: Roienigk HH, Maibach HI, editors. Psoriasis. 3rd ed. New York: Marcel Dekker; 1998. p. 107–58.Google Scholar
  5. 5.
    Kumar B, Jain R, Sandhu K, et al. Epidemiology of childhood psoriasis: a study of 419 patients from northern India. Int J Dermatol. 2004;43(9):654–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Kwon HH, Na SJ, Jo SJ, et al. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol. 2012;39(3):260–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Tollefson MM, Crowson CS, McEvoy MT, et al. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979–87.PubMedCrossRefGoogle Scholar
  8. 8.
    Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1–18.PubMedCrossRefGoogle Scholar
  9. 9.
    Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17(3):174–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Neville EA, Finn OA. Psoriasiform napkin dermatitis: a follow-up study. Br J Dermatol. 1975;92(3):279–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Farber EM, Mullen RH, Jacobs AH, et al. Infantile psoriasis: a follow-up study. Pediatr Dermatol. 1986;3(3):237–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Boje Rasmussen H, Hagdrup H, Schmidt H. Psoriasiform napkin dermatitis. Acta Derm Venereol. 1986;66(6):534–6.PubMedGoogle Scholar
  13. 13.
    Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23(5):437–43.PubMedCrossRefGoogle Scholar
  14. 14.
    Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.PubMedCrossRefGoogle Scholar
  15. 15.
    Ramsey SE, Bolaria RK, Cabral DA, et al. Comparison of criteria for the classification of childhood arthritis. J Rheumatol. 2000;27(5):1283–6.PubMedGoogle Scholar
  16. 16.
    Stoll ML, Nigrovic PA, Gotte AC, et al. Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011;29(3):582–8.PubMedGoogle Scholar
  17. 17.
    Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Au SC, Goldminz AM, Loo DS, et al. Association between pediatric psoriasis and the metabolic syndrome. J Am Acad Dermatol. 2012;66(6):1012–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011;159(4):577–83.PubMedCrossRefGoogle Scholar
  20. 20.
    Volf EM, Levine DE, Michelon MA, et al. Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts. J Drugs Dermatol. 2011;10(8):900–1.PubMedGoogle Scholar
  21. 21.
    Zamberk P, Velazquez D, Campos M, et al. Paediatric psoriasis: narrowband UVB treatment. JEADV. 2010;24(4):415–9.PubMedGoogle Scholar
  22. 22.
    Bilgic A, Bilgic O, Akis HK, et al. Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis. Pediatr Derm. 2010;27(6):614–7.CrossRefGoogle Scholar
  23. 23.
    Varni JW, Globe DR, Gandra SR, et al. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr. 2012;171(3):485–92.PubMedCrossRefGoogle Scholar
  24. 24.
    Michalak-Stoma A, Pietrzak A, Szepietowski JC, et al. Cytokine network in psoriasis revisited. Eur Cytokine Netw. 2011;22(4):160–8.PubMedGoogle Scholar
  25. 25.
    Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827–51.PubMedCrossRefGoogle Scholar
  26. 26.
    Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol. 2000;143(6):1177–82.PubMedCrossRefGoogle Scholar
  27. 27.
    Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90(5):784–95.PubMedCrossRefGoogle Scholar
  28. 28.
    Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. New Engl J Med. 2011;365(7):620–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Rahman P, Elder JT. Genetics of psoriasis and psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39(2):431–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Chandran V. The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;14(2):149–56.CrossRefGoogle Scholar
  31. 31.
    Ozden MG, Tekin NS, Gurer MA, et al. Environmental risk factors in pediatric psoriasis: a multicenter case-control study. Pediatr Dermatol. 2011;28(3):306–12.PubMedCrossRefGoogle Scholar
  32. 32.
    Rasmussen JE. The relationship between infection with group A beta hemolytic streptococci and the development of psoriasis. Pediatr Infect Dis J. 2000;19(2):153–4.PubMedGoogle Scholar
  33. 33.
    Leung DY, Travers JB, Giorno R, et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest. 1995;96(5):2106–12.PubMedCrossRefGoogle Scholar
  34. 34.
    Honig PJ. Guttate psoriasis associated with perianal streptococcal disease. J Pediatr. 1988;113(6):1037–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Owen CM, Chalmers RJ, O’Sullivan T, et al. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev. 2000;2:CD001976.PubMedGoogle Scholar
  36. 36.
    Eberhard BA, Sundel RP, Newburger JW, et al. Psoriatic eruption in Kawasaki disease. J Pediatr. 2000;137(4):578–80.PubMedCrossRefGoogle Scholar
  37. 37.
    Han MH, Jang KA, Sung KJ, et al. A case of guttate psoriasis following Kawasaki disease. Br J Dermatol. 2000;142(3):548–50.PubMedCrossRefGoogle Scholar
  38. 38.
    Kishimoto S, Muneuchi J, Takahashi Y, et al. Psoriasiform skin lesion and supprative acrodermatitis associated with Kawasaki disease followed by the treatment with infliximab: a case report. Acta Paediatr. 2010;99(7):1102–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Liao YC, Lee JY. Psoriasis in a 3-month-old infant with Kawasaki disease. Dermatol Online J. 2009;15(11):10.PubMedGoogle Scholar
  40. 40.
    Ergin S, Karaduman A, Demirkaya E, et al. Plaque psoriasis induced after Kawasaki disease. Turk J Pediatr. 2009;51(4):375–7.PubMedGoogle Scholar
  41. 41.
    Yoon SY, Oh ST, Lee JY, et al. Plaque type psoriasiform eruption following Kawasaki disease. Pediatr Dermatol. 2007;24(3):336–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Yoon SY, Oh ST, Lee JY, et al. A plaque type psoriasiform eruption following Kawasaki disease. Pediatr Dermatol. 2007;24(1):96–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Mizuno Y, Suga Y, Muramatsu S, et al. Psoriasiform and palmoplanter pustular lesions induced after Kawasaki disease. Int J Dermatol. 2006;45(9):1080–2.PubMedCrossRefGoogle Scholar
  44. 44.
    Menni S, Gualandri L, Boccardi D, et al. Association of psoriasis-like eruption and Kawasaki disease. J Dermatol. 2006;33(8):571–3.PubMedCrossRefGoogle Scholar
  45. 45.
    Tsai HJ, Wu WM, Chang YC, et al. Annular pustules in Kawasaki disease: a further case indicating the association with psoriasis? Cutis. 2003;72(5):354–6.PubMedGoogle Scholar
  46. 46.
    Zvulunov A, Greenberg D, Cagnano E, et al. Development of psoriatic lesions during acute and convalescent phases of Kawasaki disease. J Paediatr Child Health. 2003;39(3):229–31.PubMedCrossRefGoogle Scholar
  47. 47.
    Garty B, Mosseri R, Finkelstein Y. Guttate psoriasis following Kawasaki disease. Pediatr Dermatol. 2001;18(6):507–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Rogers M. Childhood psoriasis. Curr Opin Pediatr. 2002;14(4):404–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Howard R, Tsuchiya A. Adult skin disease in the pediatric patient. Dermatol Clin. 1998;16(3):593–608.PubMedCrossRefGoogle Scholar
  50. 50.
    Morris A, Rogers M, Fischer G, et al. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol. 2001;18(3):188–98.PubMedCrossRefGoogle Scholar
  51. 51.
    Nanda A, Kaur S, Kaur I, et al. Childhood psoriasis: an epidemiologic survey of 112 patients. Pediatr Dermatol. 1990;7(1):19–21.PubMedCrossRefGoogle Scholar
  52. 52.
    al-Fouzan AS, Nanda A. A survey of childhood psoriasis in Kuwait. Pediatr Dermatol. 1994;11(2):116–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Hutton KP, Orenberg EK, Jacobs AH. Childhood psoriasis. Cutis. 1987;39(1):26–7.PubMedGoogle Scholar
  54. 54.
    Rasmussen JE. Psoriasis in children. Dermatol Clin. 1986;4(1):99–106.PubMedGoogle Scholar
  55. 55.
    Nyfors A, Lemholt K. Psoriasis in children: a short review and a survey of 245 cases. Br J Dermatol. 1975;92(4):437–42.PubMedCrossRefGoogle Scholar
  56. 56.
    Herbst RA, Hoch O, Kapp A, et al. Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy. J Am Acad Dermatol. 2000;42(5 Pt 2):885–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Nyfors A. Psoriasis in children: characteristics, prognosis and therapy: a review. Acta Derm Venereol Suppl (Stockh). 1981;95:47–53.Google Scholar
  58. 58.
    Tervaert WC, Esseveld H. A study of the incidence of haemolytic streptococci in the throat in patients with psoriasis vulgaris, with reference to their role in the pathogenesis of this disease. Dermatologica. 1970;140(5):282–90.PubMedCrossRefGoogle Scholar
  59. 59.
    Whyte HJ, Baughman RD. Acute guttate psoriasis and streptococcal infection. Arch Dermatol. 1964;89:350–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Telfer NR, Chalmers RJ, Whale K, et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992;128(1):39–42.PubMedCrossRefGoogle Scholar
  61. 61.
    Cordoro KM. Management of childhood psoriasis. Adv Dermatol. 2008;24:125–69.PubMedCrossRefGoogle Scholar
  62. 62.
    Trueb RM. Therapies for childhood psoriasis. Curr Probl Dermatol. 2009;38:137–59.PubMedCrossRefGoogle Scholar
  63. 63.
    Nanda A. Concomitance of psoriasis and atopic dermatitis. Dermatology. 1995;191(1):72.PubMedCrossRefGoogle Scholar
  64. 64.
    Lever WF, Elder DE. Lever’s histopathology of the skin. 10th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009.Google Scholar
  65. 65.
    Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25(6):524–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Vogel SA, Yentzer B, Davis SA, et al. Trends in pediatric psoriasis outpatient health care delivery in the United States. Arch Dermatol. 2012;148(1):66–71.PubMedCrossRefGoogle Scholar
  67. 67.
    Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther. 2004;17(5):364–75.PubMedCrossRefGoogle Scholar
  68. 68.
    Bhutani T, Kamangar F, Cordoro KM. Management of pediatric psoriasis. Pediatr Ann. 2012;41(1):e1–7.PubMedGoogle Scholar
  69. 69.
    de Jager ME, de Jong EM, van de Kerkhof PC, et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2010;62(6):1013–30.PubMedCrossRefGoogle Scholar
  70. 70.
    Lara-Corrales I, Xi N, Pope E. Childhood psoriasis treatment: evidence published over the last 5 years. Rev Recent Clin Trials. 2011;6(1):36–43.PubMedCrossRefGoogle Scholar
  71. 71.
    Gelmetti C. Therapeutic moisturizers as adjuvant therapy for psoriasis patients. Am J Clin Dermatol. 2009;10(Suppl. 1):7–12.PubMedCrossRefGoogle Scholar
  72. 72.
    Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991;25(6 Pt 2):1166–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Kimball AB, Gold MH, Zib B, et al. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J Am Acad Dermatol. 2008;59(3):448–54, 454.e1.Google Scholar
  74. 74.
    Ahn SJ, Oh SH, Chang SE, et al. A case of infantile psoriasis with pseudoainhum successfully treated with topical pimecrolimus and low-dose narrowband UVB phototherapy. JEADV. 2006;20(10):1332–4.PubMedGoogle Scholar
  75. 75.
    Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. JEADV. 2004;18(6):742–3.PubMedGoogle Scholar
  76. 76.
    Mansouri P, Farshi S. Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J. 2006;12(2):7.PubMedGoogle Scholar
  77. 77.
    Brune A, Miller DW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24(1):76–80.PubMedCrossRefGoogle Scholar
  78. 78.
    Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol. 2005;53(4):713–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Choi YJ, Hann SK, Chang SN, et al. Infantile psoriasis: successful treatment with topical calcipotriol. Pediatr Dermatol. 2000;17(3):242–4.PubMedCrossRefGoogle Scholar
  80. 80.
    Darley CR, Cunliffe WJ, Green CM, et al. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135(3):390–3.PubMedCrossRefGoogle Scholar
  81. 81.
    Oranje AP, Marcoux D, Svensson A, et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol. 1997;36(2 Pt 1):203–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Park SB, Suh DH, Youn JI. A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol. 1999;16(4):321–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Patrizi A, Neri I, Rizzoli L, et al. Topical calcipotriol in childhood psoriasis. Acta Derm Venereol. 1999;79(6):477.PubMedCrossRefGoogle Scholar
  84. 84.
    Perez A, Chen TC, Turner A, et al. Pilot study of topical calcitriol (1,25-dihydroxyvitamin D3) for treating psoriasis in children. Arch Dermatol. 1995;131(8):961–2.PubMedCrossRefGoogle Scholar
  85. 85.
    Saggese G, Federico G, Battini R. Topical application of 1,25-dihydroxyvitamin D3 (calcitriol) is an effective and reliable therapy to cure skin lesions in psoriatic children. Eur J Pediatr. 1993;152(5):389–92.PubMedCrossRefGoogle Scholar
  86. 86.
    Travis LB, Silverberg NB. Psoriasis in infancy: therapy with calcipotriene ointment. Cutis. 2001;68(5):341–4.PubMedGoogle Scholar
  87. 87.
    Comaish JS. Tar and related compounds in the therapy of psoriasis. Clin Exp Dermatol. 1981;6(6):639–45.PubMedCrossRefGoogle Scholar
  88. 88.
    Lin AN, Moses K. Tar revisited. Int J Dermatol. 1985;24(4):216–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Borska L, Fiala Z, Krejsek J, et al. Immunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2007;24(6):607–12.PubMedCrossRefGoogle Scholar
  90. 90.
    Kortuem KR, Davis MD, Witman PM, et al. Results of Goeckerman treatment for psoriasis in children: a 21-year retrospective review. Pediatr Dermatol. 2010;27(5):518–24.PubMedCrossRefGoogle Scholar
  91. 91.
    Menter MA, Whiting DA, McWilliams J. Resistant childhood psoriasis: an analysis of patients seen in a day-care center. Pediatr Dermatol. 1984;2(1):8–12.PubMedCrossRefGoogle Scholar
  92. 92.
    Borska L, Andrys C, Krejsek J, et al. Genotoxic hazard and cellular stress in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2009;26(1):23–7.PubMedCrossRefGoogle Scholar
  93. 93.
    Diluvio L, Campione E, Paterno EJ, et al. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%. Pediatr Dermatol. 2007;24(3):332–3.PubMedCrossRefGoogle Scholar
  94. 94.
    Zvulunov A, Anisfeld A, Metzker A. Efficacy of short-contact therapy with dithranol in childhood psoriasis. Int J Dermatol. 1994;33(11):808–10.PubMedCrossRefGoogle Scholar
  95. 95.
    Guerrier CJ, Porter DI. An open assessment of 0.1% dithranol in a 17% urea base (‘Psoradrate’ 0.1%) in the treatment of psoriasis of children. Curr Med Res Opin. 1983;8(6):446–50.PubMedCrossRefGoogle Scholar
  96. 96.
    Pavlovsky M, Baum S, Shpiro D, et al. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? JEADV. 2011;25(6):727–9.PubMedGoogle Scholar
  97. 97.
    al-Fouzan AS, Nanda A. UVB phototherapy in childhood psoriasis. Pediatr Dermatol. 1995;12(1):66.PubMedCrossRefGoogle Scholar
  98. 98.
    Pasic A, Ceovic R, Lipozencic J, et al. Phototherapy in pediatric patients. Pediatr Dermatol. 2003;20(1):71–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol. 1996;13(5):406–9.PubMedCrossRefGoogle Scholar
  100. 100.
    Jain VK, Aggarwal K, Jain K, et al. Narrow-band UV-B phototherapy in childhood psoriasis. Int J Dermatol. 2007;46(3):320–2.PubMedCrossRefGoogle Scholar
  101. 101.
    Pahlajani N, Katz BJ, Lozano AM, et al. Comparison of the efficacy and safety of the 308 nm excimer laser for the treatment of localized psoriasis in adults and in children: a pilot study. Pediatr Dermatol. 2005;22(2):161–5.PubMedCrossRefGoogle Scholar
  102. 102.
    Gelfand JM, Wan J, Callis Duffin K, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148(4):487–94.PubMedCrossRefGoogle Scholar
  103. 103.
    Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001–17.PubMedCrossRefGoogle Scholar
  104. 104.
    Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(4):1263–71.PubMedCrossRefGoogle Scholar
  105. 105.
    Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–88.PubMedCrossRefGoogle Scholar
  106. 106.
    Kopp T, Karlhofer F, Szepfalusi Z, et al. Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. Br J Dermatol. 2004;151(4):912–6.PubMedCrossRefGoogle Scholar
  107. 107.
    de Oliveira ST, Maragno L, Arnone M, et al. Generalized pustular psoriasis in childhood. Pediatr Dermatol. 2010;27(4):349–54.PubMedCrossRefGoogle Scholar
  108. 108.
    Xiao T, Li B, He CD, et al. Juvenile generalized pustular psoriasis. J Dermatol. 2007;34(8):573–6.PubMedCrossRefGoogle Scholar
  109. 109.
    Juanqin G, Zhiqiang C, Zijia H. Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases. Pediatr Dermatol. 1998;15(2):144–6.PubMedCrossRefGoogle Scholar
  110. 110.
    Chao PH, Cheng YW, Chung MY. Generalized pustular psoriasis in a 6-week-old infant. Pediatr Dermatol. 2009;26(3):352–4.PubMedCrossRefGoogle Scholar
  111. 111.
    Salleras M, Sanchez-Regana M, Umbert P. Congenital erythrodermic psoriasis: case report and literature review. Pediatr Dermatol. 1995;12(3):231–4.PubMedCrossRefGoogle Scholar
  112. 112.
    Judge MR, McDonald A, Black MM. Pustular psoriasis in childhood. Clin Exp Dermatol. 1993;18(2):97–9.PubMedCrossRefGoogle Scholar
  113. 113.
    Ergin S, Ersoy-Evans S, Sahin S, et al. Acitretin is a safe treatment option for infantile pustular psoriasis. J Dermatol Treat. 2008;19(6):341–3.CrossRefGoogle Scholar
  114. 114.
    Rosinska D, Wolska H, Jablonska S, et al. Etretinate in severe psoriasis of children. Pediatr Dermatol. 1988;5(4):266–72.PubMedCrossRefGoogle Scholar
  115. 115.
    Karamfilov T, Wollina U. Juvenile generalized pustular psoriasis. Acta Derm Venereol. 1998;78(3):220.PubMedCrossRefGoogle Scholar
  116. 116.
    Shelnitz LS, Esterly NB, Honig PJ. Etretinate therapy for generalized pustular psoriasis in children. Arch Dermatol. 1987;123(2):230–3.PubMedCrossRefGoogle Scholar
  117. 117.
    Liao PB, Rubinson R, Howard R, et al. Annular pustular psoriasis: most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol. 2002;19(1):19–25.PubMedCrossRefGoogle Scholar
  118. 118.
    Al-Shobaili H, Al-Khenaizan S. Childhood generalized pustular psoriasis: successful treatment with isotretinoin. Pediatr Dermatol. 2007;24(5):563–4.PubMedCrossRefGoogle Scholar
  119. 119.
    Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60(5):824–37.PubMedCrossRefGoogle Scholar
  120. 120.
    Kumar B, Dhar S, Handa S, et al. Methotrexate in childhood psoriasis. Pediatr Dermatol. 1994;11(3):271–3.PubMedCrossRefGoogle Scholar
  121. 121.
    Dogra S, Handa S, Kanwar AJ. Methotrexate in severe childhood psoriasis. Pediatr Dermatol. 2004;21(3):283–4.PubMedCrossRefGoogle Scholar
  122. 122.
    Dogra S, Kumaran MS, Handa S, et al. Methotrexate for generalized pustular psoriasis in a 2-year-old child. Pediatr Dermatol. 2005;22(1):85–6.PubMedCrossRefGoogle Scholar
  123. 123.
    Kalla G, Goyal AM. Juvenile generalized pustular psoriasis. Pediatr Dermatol. 1996;13(1):45–6.PubMedCrossRefGoogle Scholar
  124. 124.
    Kaur I, Dogra S, De D, et al. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol. 2008;25(2):184–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Garg T, Chander R, Mittal S. Familial juvenile generalized pustular psoriasis: response to methotrexate. Skinmed. 2011;9(3):190–1.PubMedGoogle Scholar
  126. 126.
    Collin B, Vani A, Ogboli M, et al. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol. 2009;34(3):295–8.PubMedCrossRefGoogle Scholar
  127. 127.
    Scott RB, Surana R. Erythrodermic psoriasis in childhood: a young Negro child treated with methotrexate. Am J Dis Child. 1968;116(2):218–21.PubMedGoogle Scholar
  128. 128.
    Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655–62.PubMedCrossRefGoogle Scholar
  129. 129.
    Pereira TM, Vieira AP, Fernandes JC, et al. Cyclosporin A treatment in severe childhood psoriasis. JEADV. 2006;20(6):651–6.PubMedGoogle Scholar
  130. 130.
    Perrett CM, Ilchyshyn A, Berth-Jones J. Cyclosporin in childhood psoriasis. J Dermatol Treat. 2003;14(2):113–8.Google Scholar
  131. 131.
    Kilic SS, Hacimustafaoglu M, Celebi S, et al. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol. 2001;18(3):246–8.PubMedCrossRefGoogle Scholar
  132. 132.
    Alli N, Gungor E, Karakayali G, et al. The use of cyclosporin in a child with generalized pustular psoriasis. Br J Dermatol. 1998;139(4):754–5.PubMedCrossRefGoogle Scholar
  133. 133.
    Kim HS, Kim GM, Kim SY. Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy. Pediatr Dermatol. 2006;23(3):306–8.PubMedCrossRefGoogle Scholar
  134. 134.
    Nakamura S, Hashimoto Y, Igawa S, et al. Childhood generalized pustular psoriasis treated by preprandial ciclosporin administration: serum cytokine pattern during the course of the disease. Clin Exp Dermatol. 2009;34(8):e1023–4.PubMedCrossRefGoogle Scholar
  135. 135.
    Mahe E, Bodemer C, Pruszkowski A, et al. Cyclosporine in childhood psoriasis. Arch Dermatol. 2001;137(11):1532–3.PubMedGoogle Scholar
  136. 136.
    Marji JS, Marcus R, Moennich J, et al. Use of biologic agents in pediatric psoriasis. J Drugs Dermatol. 2010;9(8):975–86.PubMedGoogle Scholar
  137. 137.
    Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol. 2010;6(10):561–71.PubMedCrossRefGoogle Scholar
  138. 138.
    Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–50.PubMedCrossRefGoogle Scholar
  139. 139.
    Pontikaki I, Shahi E, Frasin LA, et al. Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2012;42(2):131–4.PubMedCrossRefGoogle Scholar
  140. 140.
    Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742–51.PubMedCrossRefGoogle Scholar
  141. 141.
    Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861–72.PubMedCrossRefGoogle Scholar
  142. 142.
    Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144(2):200–7.PubMedCrossRefGoogle Scholar
  143. 143.
    Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(2):304–14.PubMedCrossRefGoogle Scholar
  144. 144.
    Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):661–8.PubMedCrossRefGoogle Scholar
  145. 145.
    Gottlieb AB, Leonardi C, Kerdel F, et al. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):652–60.PubMedCrossRefGoogle Scholar
  146. 146.
    Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol. 2011;12(2):113–25.PubMedCrossRefGoogle Scholar
  147. 147.
    Hawrot AC, Metry DW, Theos AJ, et al. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol. 2006;23(1):67–71.PubMedCrossRefGoogle Scholar
  148. 148.
    Kress DW. Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl. 2):S126–8.PubMedCrossRefGoogle Scholar
  149. 149.
    Papoutsaki M, Costanzo A, Mazzotta A, et al. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006;154(1):181–3.PubMedCrossRefGoogle Scholar
  150. 150.
    Safa G, Loppin M, Bousser AM, et al. Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis. J Am Acad Dermatol. 2007;56(2 Suppl.):S19–20.PubMedCrossRefGoogle Scholar
  151. 151.
    Fabrizi G, Guerriero C, Pagliarello C. Etanercept in infants: suberythrodermic, recalcitrant psoriasis in a 22 month-old child successfully treated with etanercept. Eur J Dermatol. 2007;17(3):245.PubMedGoogle Scholar
  152. 152.
    Floristan U, Feltes R, Ramirez P, et al. Recalcitrant palmoplantar pustular psoriasis treated with etanercept. Pediatr Dermatol. 2011;28(3):349–50.PubMedCrossRefGoogle Scholar
  153. 153.
    Pereira TM, Vieira AP, Fernandes JC, et al. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology. 2006;213(4):350–2.PubMedCrossRefGoogle Scholar
  154. 154.
    Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. New Engl J Med. 2008;358(3):241–51.PubMedCrossRefGoogle Scholar
  155. 155.
    Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63(5):762–8.PubMedCrossRefGoogle Scholar
  156. 156.
    Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatol Treat. 2005;16(5–6):350–2.CrossRefGoogle Scholar
  157. 157.
    Alvarez AC, Rodriguez-Nevado I, De Argila D, et al. Recalcitrant pustular psoriasis successfully treated with adalimumab. Pediatr Dermatol. 2011;28(2):195–7.PubMedCrossRefGoogle Scholar
  158. 158.
    Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol. 2004;21(1):87–8.PubMedCrossRefGoogle Scholar
  159. 159.
    Farnsworth NN, George SJ, Hsu S. Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J. 2005;11(3):11.PubMedGoogle Scholar
  160. 160.
    Rott S, Kuster RM, Mrowietz U. Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko. Br J Dermatol. 2007;157(1):191–2.PubMedCrossRefGoogle Scholar
  161. 161.
    Perman MJ, Lovell DJ, Denson LA, et al. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol. 2012;29(4):454–9.PubMedCrossRefGoogle Scholar
  162. 162.
    Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52(2):230–2.PubMedCrossRefGoogle Scholar
  163. 163.
    Pourciau C, Shwayder T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr Dermatol. 2010;27(5):539–40.PubMedCrossRefGoogle Scholar
  164. 164.
    Stuart P, Malick F, Nair RP, et al. Analysis of phenotypic variation in psoriasis as a function of age at onset and family history. Arch Dermatol Res. 2002;294(5):207–13.PubMedGoogle Scholar
  165. 165.
    Ferrandiz C, Pujol RM, Garcia-Patos V, et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002;46(6):867–73.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Division of DermatologyCincinnati Children’s HospitalCincinnatiUSA

Personalised recommendations